Clinical Trials Browser

Testicular Germ Cell Tumor, Adenocarcinoma of Lung, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Adrenocortical Carcinoma, Cholangiocarcinoma

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2 Completed

373 enrolled 34 charts 2 FDA

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03891173 2022-08-12

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

Phase 2 Terminated

9 enrolled

Thoracic

Adenocarcinoma of Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Phase 2 Completed

161 enrolled 32 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02450903 2021-03-30

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Phase 2 Completed

20 enrolled 12 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02276027 2020-12-16

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

66 enrolled 18 charts

Thoracic

Adenocarcinoma of Lung

NCT04460729 2020-12-03

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Phase 2 Withdrawn

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01218516 2020-08-20

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Phase 2 Completed

130 enrolled 11 charts

Thoracic

Adenocarcinoma of Lung

NCT01646125 2019-07-24

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Phase 2 Terminated

59 enrolled 9 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01685138 2019-03-26

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Phase 2 Completed

124 enrolled 18 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03240393 2018-07-26

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Thoracic

Adenocarcinoma of Lung, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00511485 2015-02-27

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

Phase 2 Completed

43 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01561456 2013-12-05

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Phase 2 Completed

100 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT00365183 2013-10-31

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Phase 2 Terminated

74 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Clinical Trials

HARMONIC

CDK4i

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Milademetan in Advanced/Metastatic Solid Tumors

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer